CIBIT has established an agreement with APTA Therapeutics
31 dezembro, 2025≈ 1 min de leitura
CIBIT has established an agreement with APTA Therapeutics, a clinical-stage biopharmaceutical company developing DNA-based aptamer therapies, to support CIBITs planned Investigator Initiated Trial of rovunaptabin in patients with long COVID.
By combining APTA Therapeutics’ innovative therapeutic approach targeting dysfunctional regulatory autoantibodies, with CIBIT’s expertise in translational clinical research, this collaboration aims to address a high unmet medical need in long COVID and contribute to improving patients’ quality of life.